source
- Alnylam shares tumble to $250 after cutting full-year revenue guidance for its TTR franchiseAlnylam Pharmaceuticals saw its share price slide to about $250 after the company lowered its full-year revenue outlook for its transthyretin (TTR) franchise. The guidance cut, announced in July, f…
- Massachusetts moves to revoke all RegalCare nursing home licenses after Boston Globe investigationMassachusetts regulators announced on Oct 13 that they will revoke every nursing home license held by RegalCare, a New Jersey‑based operator that acquired a dozen facilities in the state after the…